3-hydroxyflavone has been researched along with Cardiac Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, G; Dai, X; Feng, J; Ge, C; Hu, LF; Kuang, Q; Lai, L; Li, H; Long, T; Sun, Y; Tan, J; Tang, T; Xiong, M; Xu, M; Yang, Q; Yi, C; Zhan, J; Zhong, S | 1 |
| Chang, L; Dai, J; Fu, Y; He, Q; Luo, P; Shao, J; Wang, J; Weng, Q; Yang, B; Yang, X; Zhu, H | 1 |
2 other study(ies) available for 3-hydroxyflavone and Cardiac Diseases
| Article | Year |
|---|---|
Oral flavonoid fisetin treatment protects against prolonged high-fat-diet-induced cardiac dysfunction by regulation of multicombined signaling.
Topics: Animals; Diet, High-Fat; Disease Models, Animal; Dyslipidemias; Echocardiography; Fibrosis; Flavonoids; Flavonols; Glucose Tolerance Test; Heart; Heart Diseases; Inflammation; Insulin; Insulin Resistance; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Myocardium; Myocytes, Cardiac; Rats; Rats, Wistar; Signal Transduction | 2020 |
Dihydromyricetin prevents cardiotoxicity and enhances anticancer activity induced by adriamycin.
Topics: Animals; Animals, Newborn; Antibiotics, Antineoplastic; Apoptosis; Cell Proliferation; Cytoprotection; Cytoskeletal Proteins; Dose-Response Relationship, Drug; Doxorubicin; Flavonols; Heart Diseases; HL-60 Cells; Humans; K562 Cells; Lymphoma, Large B-Cell, Diffuse; Mice, Inbred BALB C; Mice, Inbred ICR; Myocytes, Cardiac; Nerve Tissue Proteins; Oxidative Stress; Protective Agents; Proto-Oncogene Proteins c-mdm2; Rats; Rats, Sprague-Dawley; Signal Transduction; Time Factors; Tumor Burden; Tumor Suppressor Protein p53; U937 Cells; Xenograft Model Antitumor Assays | 2015 |